Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03006367 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD
A Phase 1 study of Attention Deficit Disorder With Hyperactivity, sponsored by Aevi Genomic Medicine, LLC, a Cerecor company.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 3
- Study locations
NCT03006367: Completed Phase 1 study of Attention Deficit Disorder With Hyperactivity, sponsored by Aevi Genomic Medicine, LLC, a Cerecor company.
NCT03006367 is a Phase 1 study of Attention Deficit Disorder With Hyperactivity that has completed, run by Aevi Genomic Medicine, LLC, a Cerecor company. The registered enrollment target is 32 participants, below the 354-participant average among 20 other Attention Deficit Disorder With Hyperactivity trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03006367, a Phase 1 study of Attention Deficit Disorder With Hyperactivity, has completed, sponsored by Aevi Genomic Medicine, LLC, a Cerecor company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a open-label, single ascending dose, pharmacokinetic, and tolerability study of NFC-1 in Children and Adolescents (Ages 6-17 Years) with ADHD.
Conditions Studied
Interventions
- DRUG NFC-1 100 mg
- DRUG NFC-1 200 mg
- DRUG NFC-1 400 mg
- DRUG NFC-1 800 mg
Study Locations (3)
Florida
- Meridien Research, Inc. - Maitland
- QPS-MRA, LLC (Miami Research Associates) - Miami
Nevada
- Center for Psychiatry and Behavioral Medicine - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2017-01-07 |
| Est. Completion | 2017-03-06 |
| Phase | Phase 1 |
What the finished NCT03006367 record still lists
NCT03006367 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 354-participant average among 20 other Attention Deficit Disorder With Hyperactivity trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Attention Deficit Disorder With Hyperactivity appearing as the primary indexed condition, and to 4 interventions - of which NFC-1 100 mg is the first listed.
NCT03006367 reports a single indexed study location in Florida, Nevada.
Frequently Asked Questions
What is clinical trial NCT03006367 about?
NCT03006367 is a clinical study titled "Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD". This is a open-label, single ascending dose, pharmacokinetic, and tolerability study of NFC-1 in Children and Adolescents (Ages 6-17 Years) with ADHD.
What is the current status of trial NCT03006367?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2017-01-07. Estimated completion is 2017-03-06.
What conditions does trial NCT03006367 study?
This clinical trial studies the following conditions: Attention Deficit Disorder With Hyperactivity.
What interventions are being tested in trial NCT03006367?
The interventions under investigation include: NFC-1 100 mg (DRUG), NFC-1 200 mg (DRUG), NFC-1 400 mg (DRUG), NFC-1 800 mg (DRUG).
Who is sponsoring clinical trial NCT03006367?
This trial is sponsored by Aevi Genomic Medicine, LLC, a Cerecor company, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03006367 being conducted?
This trial has 3 study locations across Florida, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Disorder With Hyperactivity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03006367's enrollment target sits among peer trials
32 18th of 20 higher than 3 of 20 other Attention Deficit Disorder With Hyperactivity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Attention Deficit Disorder With Hyperactivity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse
COMPLETED · Phase 1
-
Home-based Transcranial Direct Current Stimulation (tDCS) for Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)
RECRUITING · NA
-
Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers
ACTIVE NOT RECRUITING
-
Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD
COMPLETED · Phase 2
-
Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
COMPLETED · NA
-
TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI